A BioCentury analysis of the nearly 7,000 abstracts at AACR 2026 identified 176 new oncology targets proposed for future therapies. The review emphasized immuno-oncology themes, including strategies to enhance anti-tumor immune responses in solid tumors and approaches to make existing immunotherapies more effective. While the findings are early-stage and reflect research presented at a conference rather than clinical validation, they provide a structured view of where translational oncology labs are concentrating efforts. For drug developers, the list offers candidate biology and pathway direction signals for target selection and biomarker programs. The central takeaway is that immune modulation remains a major driver of new target discovery efforts, with multiple tracks aimed at overcoming resistance to immunotherapies in solid tumor settings.